Eli Lilly’s Zepbound Tops Novo Nordisk’s Wegovy in Weight-Loss Trial | Global News Avenue

Eli Lilly and Company (Li Lai) Popular weight-loss drug Zepbound outperformed Danish drugmaker Novo Nordisk’s rival drug Wegovy (non-governmental organization), according to results from a new clinical study released Wednesday.

In a randomized study involving 751 patients in the United States, sponsored by the manufacturer of Zepbound, patients took Zepp Bond During the 72-week trial, patients taking Wegovy lost an average of 20.2% of their body weight, while those taking Wegovy lost an average of 13.7% of their body weight.

That means patients taking Zepbound lost an average of about 50 pounds, while patients taking Zepbound lost an average of about 33 pounds. wiggsEli Lilly said Wednesday.

“Given the growing interest in obesity drugs, we conducted this study to help healthcare providers and patients make informed decisions about treatment options,” said Leonard Glass, senior vice president of global medical affairs at Eli Lilly and Company. “We conducted this study to help healthcare providers and patients make informed decisions about treatment options.” We are pleased that today’s findings demonstrate the superior weight loss benefits of Zepbound, helping patients achieve a 47% relative weight loss compared to Wegovy.”

Study mirrors results from a similar trial published in July

The latest results reflect another result, Larger study published Research this summer showed that tezepatide, the active ingredient in Eli Lilly and Co.’s weight-loss drug, caused greater and faster weight loss than Nordisk and Nordisk’s semaglutide.

Popularity of weight loss pills Improved Eli Lilly’s and Novo Nordisk Sales and the company’s share price last year. back Down from historical highs following the most recent earnings reportShares of drugmakers were higher last month on the news. Biden administration proposes coverage poison Through Medicare and Medicaid Treat obesity and the subsequent health problems it can cause.

Eli Lilly shares rose more than 3% on Wednesday, while Novo Nordisk’s U.S.-listed shares rose about 0.8%. Eli Lilly’s shares are up 43% this year, while Novo Nordisk’s shares are just 6% above where they will start trading in early 2024.